Oncology and Hematology - Global Oncology Academy

145-152 of 152

Diversity in HER2 Expression Among Gynecologic Cancers
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®
Diversity in HER2 Expression Among Gynecologic Cancers
Ritu Salani, MD, MBA
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
MinuteCE®
Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors
Shubham Pant, MD, MBBS; Ritu Salani, MD, MBA
0.75 credits 8 episodes
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 credits 8 episodes
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Ritu Salani, MD, MBA
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Shubham Pant, MD, MBBS; Ritu Salani, MD, MBA
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
Shubham Pant, MD, MBBS
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
Significance of HER2 Expression in Solid Tumors
Significance of HER2 Expression in Solid Tumors
MinuteCE®
Significance of HER2 Expression in Solid Tumors
Shubham Pant, MD, MBBS; Ritu Salani, MD, MBA
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Ritu Salani, MD, MBA
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
CME/CE
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
Justin Gainor, MD; Jacob Sands, MD
0.50 credits
- Justin Gainor, MD
- Jacob Sands, MD
0.50 credits

Previous
1
2
…
8
9
10
Next

10/6